Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein

Zvi Hayouka; Mattan Hurevich; Aviad Levin; Hadar Benyamini; Anat Iosub; Michal Maes; Deborah E. Shalev; Abraham Loyter; Chaim Gilon; Assaf Friedler

doi:10.1016/j.bmc.2010.09.046

Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein

Zvi Hayouka, Mattan Hurevich, Aviad Levin, Hadar Benyamini, Anat Iosub, Michal Maes, Deborah E. Shalev, Abraham Loyter, Chaim Gilon, Assaf Friedler^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Restricting linear peptides to their bioactive conformation is an attractive way of improving their stability and activity. We used a cyclic peptide library with conformational diversity for selecting an active and stable peptide that mimics the structure and activity of the HIV-1 integrase (IN) binding loop from its cellular cofactor LEDGF/p75 (residues 361-370). All peptides in the library had the same primary sequence, and differed only in their conformation. Library screening revealed that the ring size and linker structure had a huge effect on the conformation, binding and activity of the peptides. One of the cyclic peptides, c(MZ 4-1), was a potent and stable inhibitor of IN activity in vitro and in cells even after 8 days. The NMR structure of c(MZ 4-1) showed that it obtains a bioactive conformation that is similar to the parent site in LEDGF/p75.

Original language	English
Pages (from-to)	8388-8395
Number of pages	8
Journal	Bioorganic and Medicinal Chemistry
Volume	18
Issue number	23
DOIs	https://doi.org/10.1016/j.bmc.2010.09.046
State	Published - 1 Dec 2010

Bibliographical note

Funding Information:
A.F. is supported by a starting grant from the European Research Council under the European Community’s Seventh Framework Programme ( FP7/2007-2013 )/ERC Grant agreement n° 203413. A.L. is supported by the Israel Science Foundation (ISF; Grant No. 888/05 ). H.B is supported by a fellowship from the Israel Cancer research Foundation (ICRF). Some molecular graphics images were produced using the Chimera package from the University of California, San Francisco (supported by NIH P41 RR-01081).

Keywords

Cyclic peptides
HIV-1
Intergase inhibitors
NMR
Protein mimetics
Protein-protein interactions

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bmc.2010.09.046

Cite this

@article{9414148d00ca4d43b991c0193c3d4642,

title = "Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein",

abstract = "Restricting linear peptides to their bioactive conformation is an attractive way of improving their stability and activity. We used a cyclic peptide library with conformational diversity for selecting an active and stable peptide that mimics the structure and activity of the HIV-1 integrase (IN) binding loop from its cellular cofactor LEDGF/p75 (residues 361-370). All peptides in the library had the same primary sequence, and differed only in their conformation. Library screening revealed that the ring size and linker structure had a huge effect on the conformation, binding and activity of the peptides. One of the cyclic peptides, c(MZ 4-1), was a potent and stable inhibitor of IN activity in vitro and in cells even after 8 days. The NMR structure of c(MZ 4-1) showed that it obtains a bioactive conformation that is similar to the parent site in LEDGF/p75.",

keywords = "Cyclic peptides, HIV-1, Intergase inhibitors, NMR, Protein mimetics, Protein-protein interactions",

author = "Zvi Hayouka and Mattan Hurevich and Aviad Levin and Hadar Benyamini and Anat Iosub and Michal Maes and Shalev, {Deborah E.} and Abraham Loyter and Chaim Gilon and Assaf Friedler",

note = "Funding Information: A.F. is supported by a starting grant from the European Research Council under the European Community{\textquoteright}s Seventh Framework Programme ( FP7/2007-2013 )/ERC Grant agreement n° 203413. A.L. is supported by the Israel Science Foundation (ISF; Grant No. 888/05 ). H.B is supported by a fellowship from the Israel Cancer research Foundation (ICRF). Some molecular graphics images were produced using the Chimera package from the University of California, San Francisco (supported by NIH P41 RR-01081). ",

year = "2010",

month = dec,

day = "1",

doi = "10.1016/j.bmc.2010.09.046",

language = "אנגלית",

volume = "18",

pages = "8388--8395",

journal = "Bioorganic and Medicinal Chemistry",

issn = "0968-0896",

publisher = "Elsevier Ltd.",

number = "23",

}

TY - JOUR

T1 - Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein

AU - Hayouka, Zvi

AU - Hurevich, Mattan

AU - Levin, Aviad

AU - Benyamini, Hadar

AU - Iosub, Anat

AU - Maes, Michal

AU - Shalev, Deborah E.

AU - Loyter, Abraham

AU - Gilon, Chaim

AU - Friedler, Assaf

N1 - Funding Information: A.F. is supported by a starting grant from the European Research Council under the European Community’s Seventh Framework Programme ( FP7/2007-2013 )/ERC Grant agreement n° 203413. A.L. is supported by the Israel Science Foundation (ISF; Grant No. 888/05 ). H.B is supported by a fellowship from the Israel Cancer research Foundation (ICRF). Some molecular graphics images were produced using the Chimera package from the University of California, San Francisco (supported by NIH P41 RR-01081).

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Restricting linear peptides to their bioactive conformation is an attractive way of improving their stability and activity. We used a cyclic peptide library with conformational diversity for selecting an active and stable peptide that mimics the structure and activity of the HIV-1 integrase (IN) binding loop from its cellular cofactor LEDGF/p75 (residues 361-370). All peptides in the library had the same primary sequence, and differed only in their conformation. Library screening revealed that the ring size and linker structure had a huge effect on the conformation, binding and activity of the peptides. One of the cyclic peptides, c(MZ 4-1), was a potent and stable inhibitor of IN activity in vitro and in cells even after 8 days. The NMR structure of c(MZ 4-1) showed that it obtains a bioactive conformation that is similar to the parent site in LEDGF/p75.

AB - Restricting linear peptides to their bioactive conformation is an attractive way of improving their stability and activity. We used a cyclic peptide library with conformational diversity for selecting an active and stable peptide that mimics the structure and activity of the HIV-1 integrase (IN) binding loop from its cellular cofactor LEDGF/p75 (residues 361-370). All peptides in the library had the same primary sequence, and differed only in their conformation. Library screening revealed that the ring size and linker structure had a huge effect on the conformation, binding and activity of the peptides. One of the cyclic peptides, c(MZ 4-1), was a potent and stable inhibitor of IN activity in vitro and in cells even after 8 days. The NMR structure of c(MZ 4-1) showed that it obtains a bioactive conformation that is similar to the parent site in LEDGF/p75.

KW - Cyclic peptides

KW - HIV-1

KW - Intergase inhibitors

KW - NMR

KW - Protein mimetics

KW - Protein-protein interactions

UR - http://www.scopus.com/inward/record.url?scp=78249283226&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2010.09.046

DO - 10.1016/j.bmc.2010.09.046

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 20974536

AN - SCOPUS:78249283226

SN - 0968-0896

VL - 18

SP - 8388

EP - 8395

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

IS - 23

ER -

Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this